Literature DB >> 16175031

Glucocorticoids in the treatment of severe sepsis and septic shock.

Djillali Annane1.   

Abstract

PURPOSE OF REVIEW: Septic shock remains one of the leading causes of death in intensive care units. In recent years, there is general use of low to moderate doses of corticosteroids in the treatment of septic shock. However, there are wide variations in the practical modality of this treatment, mainly with regard to patients' selection, treatment's dose, timing, route of administration, duration, and weaning. This review provides opinion-based guidelines for the use of corticosteroids in severe sepsis and septic shock. RECENT
FINDINGS: A summary of the latest understanding of the mechanisms of action of corticosteroids and the most recent observations in the clinical and biologic responses to corticosteroids in severe sepsis and septic shock is presented.
SUMMARY: In septic shock, intravenous hydrocortisone should be started immediately after a 250 microg corticotropin test, at a dose of 200-300 mg per day. When adrenal insufficiency is confirmed, treatment should be continued at full doses for 7 days. Otherwise, hydrocortisone should be stopped. It is worth considering adding enteral fludrocortisone at a dose of 50 microg per day for 7 days. In severe sepsis, despite growing evidence to support the use of a moderate dose of corticosteroids, the efficacy and safety of this treatment needs to be assessed in a large-scale study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175031     DOI: 10.1097/01.ccx.0000176691.95562.43

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  13 in total

Review 1.  Extra-adrenal glucocorticoid synthesis in the intestinal epithelium: more than a drop in the ocean?

Authors:  Mario Noti; Daniel Sidler; Thomas Brunner
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

2.  Hydrocortisone and Ascorbic Acid Synergistically Prevent and Repair Lipopolysaccharide-Induced Pulmonary Endothelial Barrier Dysfunction.

Authors:  Nektarios Barabutis; Vikramjit Khangoora; Paul E Marik; John D Catravas
Journal:  Chest       Date:  2017-07-21       Impact factor: 9.410

3.  Physiologic responses to severe hemorrhagic shock and the genesis of cardiovascular collapse: can irreversibility be anticipated?

Authors:  Hernando Gómez; Jaume Mesquida; Linda Hermus; Patricio Polanco; Hyung Kook Kim; Sven Zenker; Andrés Torres; Rajaie Namas; Yoram Vodovotz; Gilles Clermont; Juan Carlos Puyana; Michael R Pinsky
Journal:  J Surg Res       Date:  2012-03-10       Impact factor: 2.192

4.  Relationship of basal heart rate variability to in vivo cytokine responses after endotoxin exposure.

Authors:  Badar U Jan; Susette M Coyle; Marie A Macor; Michael Reddell; Steve E Calvano; Stephen F Lowry
Journal:  Shock       Date:  2010-04       Impact factor: 3.454

5.  Adjunct therapy for sepsis: how early?

Authors:  Djillali Annane
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

Review 6.  Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury.

Authors:  Suzanne Heemskerk; Rosalinde Masereeuw; Frans G M Russel; Peter Pickkers
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 7.  Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Sofie Louise Rygård; Ethan Butler; Anders Granholm; Morten Hylander Møller; Jeremy Cohen; Simon Finfer; Anders Perner; John Myburgh; Balasubramanian Venkatesh; Anthony Delaney
Journal:  Intensive Care Med       Date:  2018-05-14       Impact factor: 17.440

8.  The role of MAP kinase phosphatase-1 in the protective mechanism of dexamethasone against endotoxemia.

Authors:  Xianxi Wang; Leif D Nelin; Joshua R Kuhlman; Xiaomei Meng; Stephen E Welty; Yusen Liu
Journal:  Life Sci       Date:  2008-09-21       Impact factor: 5.037

9.  Protective effect of Xuebijing injection on paraquat-induced pulmonary injury via down-regulating the expression of p38 MAPK in rats.

Authors:  Ming-wei Liu; Mei-xian Su; Wei Zhang; Yan-qiong Wang; Mei Chen; Li Wang; Chuan-yun Qian
Journal:  BMC Complement Altern Med       Date:  2014-12-16       Impact factor: 3.659

10.  ISG12 is a critical modulator of innate immune responses in murine models of sepsis.

Authors:  P Uhrin; T Perkmann; B Binder; G Schabbauer
Journal:  Immunobiology       Date:  2013-04-19       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.